Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 2-3/2010

01.04.2010

Sjögren Syndrome or Sjögren Disease? The Histological and Immunological Bias Caused by the 2002 Criteria

verfasst von: Manuel Ramos-Casals, Pilar Brito-Zerón, Marta Perez-De-Lis, Iratxe Jimenez, Maria-Jose Blanco, Albert Bove, Maria-Jose Soto, Miriam Akasbi, Candido Diaz, Juan Sentís, Antoni Siso

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2-3/2010

Einloggen, um Zugang zu erhalten

Abstract

The current 2002 classification criteria do not cover the broad clinical and immunological heterogeneity of primary Sjögren syndrome (SS), since five of the six criteria focus exclusively on glandular involvement and the remaining criterion is the mandatory presence of anti-Ro/La antibodies. The aim of this study was to analyze the clinical features of patients with a well-established diagnosis of primary SS who do not fulfill the 2002 classification criteria. Five hundred seven patients diagnosed with primary SS (1993 criteria) were consecutively included and followed up. Two hundred twenty-one (44%) patients did not fulfill the 2002 criteria. These patients were older at diagnosis (p < 0.001) and had a lower frequency of parotid enlargement (p = 0.002), fever (p = 0.041), arthritis (p = 0.041), vasculitis (p = 0.050), peripheral neuropathy (p = 0.002), cranial nerve involvement (p = 0.015), raised erythrocyte sedimentation rate ( ESR) levels (p < 0.001), anemia (p < 0.001), leukopenia (p = 0.037), hypergammaglobulinemia (p < 0.001), positive rheumatoid factor ( RF; p = 0.002), and cryoglobulinemia (p = 0.049) in comparison with those fulfilling 2002 criteria. However, there were no significant differences in the prevalence of sicca features, diagnostic tests, overall systemic involvement, antinuclear antibodies , complement levels, development of B-cell lymphoma, or survival. Patients with anti-Ro antibodies had the highest frequencies of systemic features, hematological abnormalities, and altered immunological markers. In conclusion, patients fulfilling the 2002 criteria, who have either a specific histological diagnosis (lymphocytic infiltration) or highly specific autoantibodies (Ro/La), might well be considered to have Sjögren “disease.” In contrast, etiopathogenic mechanisms other than lymphocytic-mediated epithelial damage could be involved in patients with negative Ro and negative biopsy, in whom the term Sjögren “syndrome” seems more adequate.
Literatur
2.
Zurück zum Zitat Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity and prime time for autoimmunity. J Autoimmun 31:325–330CrossRefPubMed Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity and prime time for autoimmunity. J Autoimmun 31:325–330CrossRefPubMed
3.
Zurück zum Zitat Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 164:1275–1284CrossRefPubMed Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 164:1275–1284CrossRefPubMed
4.
Zurück zum Zitat Ramos-Casals M, Tzioufas AG, Font J (2005) Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 64:347–354CrossRefPubMed Ramos-Casals M, Tzioufas AG, Font J (2005) Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 64:347–354CrossRefPubMed
5.
Zurück zum Zitat Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM et al (1993) the European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 36:340–347CrossRefPubMed Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM et al (1993) the European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 36:340–347CrossRefPubMed
6.
Zurück zum Zitat Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMed Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMed
8.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. IARC, Lyon Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. IARC, Lyon
9.
Zurück zum Zitat Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46:741–747CrossRefPubMed Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 46:741–747CrossRefPubMed
10.
Zurück zum Zitat Theander E, Manthorpe R, Jacobsson LT (2004) Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 50:1262–1269CrossRefPubMed Theander E, Manthorpe R, Jacobsson LT (2004) Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 50:1262–1269CrossRefPubMed
11.
Zurück zum Zitat Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA (2006) Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 45(2):187–191CrossRef Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA (2006) Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 45(2):187–191CrossRef
12.
Zurück zum Zitat Alexander EL, Arnett FC, Provost TT, Stevens MB (1983) Sjögren's syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities and serologic hyperreactivity. Ann Intern Med 98:155–159PubMed Alexander EL, Arnett FC, Provost TT, Stevens MB (1983) Sjögren's syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities and serologic hyperreactivity. Ann Intern Med 98:155–159PubMed
13.
Zurück zum Zitat Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, GEMESS Study Group et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87:210–219CrossRef Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, GEMESS Study Group et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87:210–219CrossRef
14.
Zurück zum Zitat Lee M, Rutka JA, Slomovic AR, McComb J, Bailey DJ, Bookman AA (1998) Establishing guidelines for the role of minor salivary gland biopsy in clinical practice for Sjögren's syndrome. J Rheumatol 25:247–253PubMed Lee M, Rutka JA, Slomovic AR, McComb J, Bailey DJ, Bookman AA (1998) Establishing guidelines for the role of minor salivary gland biopsy in clinical practice for Sjögren's syndrome. J Rheumatol 25:247–253PubMed
15.
Zurück zum Zitat Morbini P, Manzo A, Caporali R, Epis O, Villa C, Tinelli C et al (2005) Multilevel examination of minor salivary gland biopsy for Sjogren's syndrome significantly improves diagnostic performance of AECG classification criteria. Arthritis Res Ther 7:R343–R348CrossRefPubMed Morbini P, Manzo A, Caporali R, Epis O, Villa C, Tinelli C et al (2005) Multilevel examination of minor salivary gland biopsy for Sjogren's syndrome significantly improves diagnostic performance of AECG classification criteria. Arthritis Res Ther 7:R343–R348CrossRefPubMed
16.
Zurück zum Zitat Kessel A, Toubi E, Rozenbaum M, Zisman D, Sabo E, Rosner I (2006) Sjögren's syndrome in the community: can serology replace salivary gland biopsy? Rheumatol Int 26:337–339CrossRefPubMed Kessel A, Toubi E, Rozenbaum M, Zisman D, Sabo E, Rosner I (2006) Sjögren's syndrome in the community: can serology replace salivary gland biopsy? Rheumatol Int 26:337–339CrossRefPubMed
17.
Zurück zum Zitat Radfar L, Kleiner DE, Fox PC, Pillemer SR (2002) Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 47:520–524CrossRefPubMed Radfar L, Kleiner DE, Fox PC, Pillemer SR (2002) Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 47:520–524CrossRefPubMed
18.
Zurück zum Zitat Vivino FB, Gala I, Hermann GA (2002) Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol 29:938–944PubMed Vivino FB, Gala I, Hermann GA (2002) Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol 29:938–944PubMed
19.
Zurück zum Zitat Manthorpe R, Benoni C, Jacobsson L, Kirtava Z, Larsson A, Liedholm R et al (2000) Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome? Ann Rheum Dis 59:54–60CrossRefPubMed Manthorpe R, Benoni C, Jacobsson L, Kirtava Z, Larsson A, Liedholm R et al (2000) Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome? Ann Rheum Dis 59:54–60CrossRefPubMed
20.
Zurück zum Zitat Ramos-Casals M, Brito-Zerón P, Font J (2007) Lessons from diseases mimicking Sjögren's syndrome. Clin Rev Allergy Immunol 32:275–283CrossRefPubMed Ramos-Casals M, Brito-Zerón P, Font J (2007) Lessons from diseases mimicking Sjögren's syndrome. Clin Rev Allergy Immunol 32:275–283CrossRefPubMed
21.
Zurück zum Zitat Ramos-Casals M, Brito-Zerón P, Font J (2007) The overlap of Sjögren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum 36:246–255CrossRefPubMed Ramos-Casals M, Brito-Zerón P, Font J (2007) The overlap of Sjögren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum 36:246–255CrossRefPubMed
22.
Zurück zum Zitat Brito-Zerón P, Ramos-Casals M, Bove A, Sentis J, Font J (2007) Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 46:1359–1362CrossRef Brito-Zerón P, Ramos-Casals M, Bove A, Sentis J, Font J (2007) Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 46:1359–1362CrossRef
23.
Zurück zum Zitat Caporali R, Bonacci E, Epis O, Bobbio-Pallavicini F, Morbini P, Montecucco C (2008) Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum 59:714–720CrossRefPubMed Caporali R, Bonacci E, Epis O, Bobbio-Pallavicini F, Morbini P, Montecucco C (2008) Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum 59:714–720CrossRefPubMed
24.
Zurück zum Zitat Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological and epidemiological aspects. Ann Rheum Dis 60:467–472CrossRefPubMed Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological and epidemiological aspects. Ann Rheum Dis 60:467–472CrossRefPubMed
25.
Zurück zum Zitat Kruize AA, Hene RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP et al (1996) Long-term follow-up of patients with Sjögren's syndrome. Arthritis Rheum 39:297–303CrossRefPubMed Kruize AA, Hene RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP et al (1996) Long-term follow-up of patients with Sjögren's syndrome. Arthritis Rheum 39:297–303CrossRefPubMed
26.
Zurück zum Zitat Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL (1999) Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976–1992. J Rheumatol 26:1296–1300PubMed Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL (1999) Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976–1992. J Rheumatol 26:1296–1300PubMed
27.
Zurück zum Zitat Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of Primary Sjogren's syndrome. Semin Arthritis Rheum 29:296–304CrossRefPubMed Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of Primary Sjogren's syndrome. Semin Arthritis Rheum 29:296–304CrossRefPubMed
28.
Zurück zum Zitat Petri M (2005) Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am 31:245–254CrossRefPubMed Petri M (2005) Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am 31:245–254CrossRefPubMed
29.
Zurück zum Zitat Daridon C, Guerrier T, Devauchelle V, Saraux A, Pers JO, Youinou P (2007) Polarization of B effector cells in Sjögren's syndrome. Autoimmun Rev 6:427–431CrossRefPubMed Daridon C, Guerrier T, Devauchelle V, Saraux A, Pers JO, Youinou P (2007) Polarization of B effector cells in Sjögren's syndrome. Autoimmun Rev 6:427–431CrossRefPubMed
30.
Zurück zum Zitat Terzoglou AG, Routsias JG, Sakarellos C, Sakarellos-Daitsiotis M, Moutsopoulos HM, Tzioufas AG (2003) Linear epitopes of two different autoantigens-La/SSB and myelin basic protein–with a high degree of molecular similarity, cause different humoral immune responses. J Autoimmun 21:47–57CrossRefPubMed Terzoglou AG, Routsias JG, Sakarellos C, Sakarellos-Daitsiotis M, Moutsopoulos HM, Tzioufas AG (2003) Linear epitopes of two different autoantigens-La/SSB and myelin basic protein–with a high degree of molecular similarity, cause different humoral immune responses. J Autoimmun 21:47–57CrossRefPubMed
31.
Zurück zum Zitat Salomonsson S, Wahren-Herlenius M (2003) Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjögren's syndrome. Scand J Rheumatol 32:79–82CrossRefPubMed Salomonsson S, Wahren-Herlenius M (2003) Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjögren's syndrome. Scand J Rheumatol 32:79–82CrossRefPubMed
32.
Zurück zum Zitat Reed JH, Jackson MW, Gordon TP (2008) B cell apotopes of the 60-kDa Ro/SSA and La/SSB autoantigens. J Autoimmun 31:263–267CrossRefPubMed Reed JH, Jackson MW, Gordon TP (2008) B cell apotopes of the 60-kDa Ro/SSA and La/SSB autoantigens. J Autoimmun 31:263–267CrossRefPubMed
33.
Zurück zum Zitat Ferraccioli G, Tolusso B (2007) Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev 7:109–113CrossRefPubMed Ferraccioli G, Tolusso B (2007) Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev 7:109–113CrossRefPubMed
34.
Zurück zum Zitat Tengnér P, Halse AK, Haga HJ, Jonsson R, Wahren-Herlenius M (1998) Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome. Arthritis Rheum 41:2238–2248CrossRefPubMed Tengnér P, Halse AK, Haga HJ, Jonsson R, Wahren-Herlenius M (1998) Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome. Arthritis Rheum 41:2238–2248CrossRefPubMed
35.
Zurück zum Zitat Le Pottier L, Devauchelle V, Pers JO, Jamin C, Youinou P (2007) The mosaic of B-cell subsets (with special emphasis on primary Sjögren's syndrome). Autoimmun Rev 6:149–154CrossRefPubMed Le Pottier L, Devauchelle V, Pers JO, Jamin C, Youinou P (2007) The mosaic of B-cell subsets (with special emphasis on primary Sjögren's syndrome). Autoimmun Rev 6:149–154CrossRefPubMed
Metadaten
Titel
Sjögren Syndrome or Sjögren Disease? The Histological and Immunological Bias Caused by the 2002 Criteria
verfasst von
Manuel Ramos-Casals
Pilar Brito-Zerón
Marta Perez-De-Lis
Iratxe Jimenez
Maria-Jose Blanco
Albert Bove
Maria-Jose Soto
Miriam Akasbi
Candido Diaz
Juan Sentís
Antoni Siso
Publikationsdatum
01.04.2010
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2-3/2010
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8152-z

Weitere Artikel der Ausgabe 2-3/2010

Clinical Reviews in Allergy & Immunology 2-3/2010 Zur Ausgabe

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.